Effect of Ferrlecit® Versus Oral Iron on Iron Deficient Chronic Kidney Disease (CKD) Patients Receiving Erythropoietic Agents

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This study compares the effect of Ferrlecit® (a form of intravenous iron) to ferrous sulfate (a form of oral iron) in treating anemia and iron deficiency in chronic kidney disease patients who are receiving erythropoietic agents, such as Procrit® and Aranesp®.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Watson Pharmaceuticals
• Treatments: Ferric Compounds; Ferric gluconate; Iron

Criteria

Inclusion Criteria:

• Moderate to severe anemia

• Iron deficiency

• Moderate to severe chronic kidney disease

• Receiving therapy with erythropoietic agent

Exclusion Criteria:

• Receiving dialysis

• Known sensitivity to Ferrlecit® or any of its components

• Clinically unstable